Literature DB >> 16040981

T-cell-stimulating protein A elicits immune responses during meningococcal carriage and human disease.

Karen Robinson1, Karl G Wooldridge, Damien B Wells, Amal Hasan, Ian Todd, Adrian Robins, Richard James, Dlawer A A Ala'Aldeen.   

Abstract

In recognition of the need for immunological memory-inducing components for future Neisseria meningitidis group B vaccines, we previously searched the proteome of N. meningitidis and identified T-cell-stimulating protein A (TspA). This study was designed to confirm the immunogencity of TspA and to examine the subset of T-helper cell responses to the protein in patients and nasopharyngeal carriers. The tspA gene was reconstructed, cloned, and expressed in Escherichia coli, and the recombinant TspA (rTspA) protein was affinity purified. T-cell proliferative responses to rTspA were detected in the peripheral blood mononuclear cells (PBMCs) of convalescent patients and carriers, confirming that TspA-specific T-cell responses were stimulated by invasive disease and nasopharyngeal colonization. Following stimulation of PBMCs with meningococcal lysate, increased frequencies of both Th1 and Th2 cells were observed, indicating that, as during carriage, invasive meningococcal disease induced an unbiased T-helper subset response. A similar unbiased T-helper response was also detected against rTspA in the PBMCs of convalescent patients. The response of PBMCs from the carriers to TspA stimulation, however, was very weak, and the frequencies of cytokine-positive CD4 cells were not significantly greater than the frequencies in unstimulated control cultures. All of the patients and carriers responded with serum antimeningococcal immunoglobulin G (IgG) antibodies, while four of six samples from patients and 5 of 14 samples from carriers contained detectable anti-rTspA IgG antibodies. Taken together, the results of this study confirmed the immunogenicity of TspA in humans during natural meningococcal infection, and therefore, TspA is worthy of further investigation as a possible T-cell stimulating component of future vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16040981      PMCID: PMC1201220          DOI: 10.1128/IAI.73.8.4684-4693.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

Review 1.  TPR proteins: the versatile helix.

Authors:  Luca D D'Andrea; Lynne Regan
Journal:  Trends Biochem Sci       Date:  2003-12       Impact factor: 13.807

Review 2.  The immunopathogenesis of meningococcal disease.

Authors:  A J Kvalsvig; D J Unsworth
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

Review 3.  The epidemiology of acute meningitis in children in England and Wales.

Authors:  K L Davison; M E Ramsay
Journal:  Arch Dis Child       Date:  2003-08       Impact factor: 3.791

4.  Cell wall attachment of a widely distributed peptidoglycan binding domain is hindered by cell wall constituents.

Authors:  Anton Steen; Girbe Buist; Kees J Leenhouts; Mohamed El Khattabi; Froukje Grijpstra; Aldert L Zomer; Gerard Venema; Oscar P Kuipers; Jan Kok
Journal:  J Biol Chem       Date:  2003-04-08       Impact factor: 5.157

Review 5.  Vaccine prevention of meningococcal disease, coming soon?

Authors:  S L Morley; A J Pollard
Journal:  Vaccine       Date:  2001-12-12       Impact factor: 3.641

Review 6.  Neisseria meningitidis serogroup B: laboratory correlates of protection.

Authors:  Clementien Vermont; Germie van den Dobbelsteen
Journal:  FEMS Immunol Med Microbiol       Date:  2002-10-11

7.  Identification and characterization of TspA, a major CD4(+) T-cell- and B-cell-stimulating Neisseria-specific antigen.

Authors:  G Kizil; I Todd; M Atta; S P Borriello; K Ait-Tahar; D A Ala'Aldeen
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

8.  Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease.

Authors:  J Holst; B Feiring; J E Fuglesang; E A Høiby; H Nøkleby; I S Aaberge; E Rosenqvist
Journal:  Vaccine       Date:  2003-01-30       Impact factor: 3.641

9.  Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.

Authors:  Caroline L Trotter; Nick J Andrews; Edward B Kaczmarski; Elizabeth Miller; Mary E Ramsay
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

10.  Evidence for naturally acquired T cell-mediated mucosal immunity to Neisseria meningitidis.

Authors:  Victoria Davenport; Terry Guthrie; Jamie Findlow; Ray Borrow; Neil A Williams; Robert S Heyderman
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

View more
  2 in total

1.  The peptidoglycan-binding protein FimV promotes assembly of the Pseudomonas aeruginosa type IV pilus secretin.

Authors:  Hania Wehbi; Eder Portillo; Hanjeong Harvey; Anthony E Shimkoff; Edie M Scheurwater; P Lynne Howell; Lori L Burrows
Journal:  J Bacteriol       Date:  2010-11-19       Impact factor: 3.490

2.  Opa+ and Opa- isolates of Neisseria meningitidis and Neisseria gonorrhoeae induce sustained proliferative responses in human CD4+ T cells.

Authors:  Abdel-Rahman Youssef; Michiel van der Flier; Silvia Estevão; Nico G Hartwig; Peter van der Ley; Mumtaz Virji
Journal:  Infect Immun       Date:  2009-08-31       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.